AMICUS THERAPEUTICS INC (FOLD)
US03152W1099 - Common Stock
Amicus Therapeutics Becomes Oversold (FOLD)
WuXi Biologics Reports Solid 2023 Annual Results
Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong...
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K., and Germany ...
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -...
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across...
First Week of FOLD March 15th Options Trading
Amicus Therapeutics Breaks Below 200-Day Moving Average - Notable for FOLD
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand...
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief...
First Week of February 2024 Options Trading For Amicus Therapeutics (FOLD)
FOLD Makes Bullish Cross Above Critical Moving Average
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to...
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.
Amicus Therapeutics files to sell 2.5M shares for holders (NASDAQ:FOLD)
Selling stockholders of Amicus Therapeutics (FOLD) to offer 2.5 million shares for sale, with the company not receiving any proceeds.
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafold® Quarterly Revenue Surpasses $100M for the First Time ...
Commit To Buy Amicus Therapeutics At $10, Earn 18.5% Annualized Using Options
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
Notable Friday Option Activity: GME, FOLD, TGT